Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Last Update: May 06, 2025
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
ClinicalTrials.gov Identifier:
NCT06840392
Novartis Reference Number:CLOU064J12302
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS). The total duration of the study is 76 weeks and consists of: Screening (up to 4 weeks), Treatment Period 1 (16 weeks, double-blind treatment with remibrutinib (Dose A or Dose B) or placebo, Treatment Period 2 (52 weeks, treatment with remibrutinib (Dose A or Dose B) and Safety Follow-Up (treatment-free follow-up for 4 weeks).

Participants who prematurely discontinue study treatment (either during Treatment Period 1 or Treatment Period 2) are encouraged to remain in the study. Participants who do not wish to remain in the study will enter a 4-week Safety Follow-Up period.

Condition
Hidradenitis Suppurativa
Phase
Phase3
Overall Status
Recruiting
Number of Participants
555
Start Date
Mar 20, 2025
Completion Date
Oct 20, 2028
Gender
All

Age(s)
18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug

Placebo 1

Placebo matching to remibrutinib Dose A (oral)
Drug

Placebo 2

Placebo matching to remibrutinib Dose B (oral)
Drug

Remibrutinib Dose A

Remibrutinib Dose A (oral)
Drug

Remibrutinib Dose B

Remibrutinib Dose B (oral)

Eligibility Criteria

Key Inclusion Criteria:

1. Male and female participants ≥ 18 years of age at the time of signing of the informed consent.
2. Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the Baseline visit.
3. Participants with moderate to severe HS defined as:

* A total of at least 5 AN count (abscesses and/or inflammatory nodules) AND
* Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae)

Key Exclusion Criteria:

1. Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline.
2. Any active skin disease or conditions that may interfere with the assessment of HS.
3. Previous exposure to remibrutinib or other BTK inhibitors.
4. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer.
5. Significant bleeding risk or coagulation disorders.
6. History of gastrointestinal bleeding.
7. Requirement for anti-platelet (except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d) or anti-coagulant medication.

8. History or current hepatic disease.
9. Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
10. History of hypersensitivity to any of the study drug constituents.
11. Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the trial as per investigator's assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility.
12. History of live attenuated vaccine administration within 6 weeks prior to randomization or requirement to receive these vaccinations at any time while on study treatment.
13. Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Argentina

Novartis Investigative Site

Recruiting

Caba,C1012aay,Argentina

Canada

Novartis Investigative Site

Recruiting

Montreal,Quebec,H1y 3l1,Canada

Novartis Investigative Site

Recruiting

Quebec,J1g 1x9,Canada

Novartis Investigative Site

Recruiting

London,Ontario,N6h 5l5,Canada

Malaysia

Novartis Investigative Site

Recruiting

Ipoh,Perak,30450,Malaysia

Novartis Investigative Site

Recruiting

Kota Kinabalu,Sabah,88586,Malaysia

Novartis Investigative Site

Recruiting

Wilayah Persekutuan,62502,Malaysia

United States

Ohio State University

Recruiting

Columbus,Ohio,43210,United States

Robert Furlong

Phone: 614-293-4434
Email: robert.furlong@osumc.edu

Jessica Kaffenberger

Endeavor Health

Recruiting

Glenview,Illinois,60077,United States

Joseph Binder

Email: jbinder@northshore.org

Shannon Ewing

Complexions Dermatology

Recruiting

Danville,Virginia,24541,United States

Keith Robinson

Janaya Patron

Email: janaya.patron@careaccess.com

Austin Inst for Clinical Research

Recruiting

Pflugerville,Texas,78660,United States

Edward Lain

Jenna McMinn

Phone: 512-259-2545
Email: jmcminn@atxresearch.com

Vivida Dermatology

Recruiting

Las Vegas,Nevada,89148,United States

Victoria Farley

Center for Clinical Studies-Lee

Recruiting

Webster,Texas,77598,United States

Deborah Yetman

Phone: 281-333-2288
Email: dyetman@ccstexas.com

Patricia C Lee

Rivergate Dermatology and Skin Care Center

Recruiting

Goodlettsville,Tennessee,37072-2301,United States

Mary Smith

Phone: 615-859-0900
Email: mary.smith@objective.health

Keith H Loven

Floridian Research Institute

Recruiting

Miami,Florida,33179,United States

Yusmara Villa

Email: yvilla@floridianresearch.com

Gretel Trullenque

Wright State University

Recruiting

Fairborn,Ohio,45324,United States

Phone: 937-245-7500

Craig Rohan

North Shore University Hospital

Recruiting

New Hyde Park,New York,11040,United States

Amit Garg

Kirendra Pasram

Phone: 516-719-3376
Email: kpasram1@northwell.edu

Accurate Clinical Research

Recruiting

Humble,Texas,77346,United States

Chinelo Fangtang

Irene Noblitt

Email: inoblitt@accurateclinicalmanagement.com

Grady Hospital Corporation

Recruiting

Atlanta,Georgia,30303,United States

Lauren Orenstein

Southern IN Clinical Trials

Recruiting

New Albany,Indiana,47150,United States

Christy Nardi

Email: cnardi@soinct.com

Megan Landis

Ctr Dermatology and Plastic Surgery

Recruiting

Scottsdale,Arizona,85260,United States

Kenneth Steil

Stephen Fuller

Email: stephenfuller@cctresearch.com

Total Skin and Beauty Dermatology Center PC

Recruiting

Birmingham,Alabama,35205,United States

Angela Powell

Email: angela@totalskinandbeauty.com

Rajini Murthy

Forefront Dermatology

Recruiting

Vienna,Virginia,22182,United States

Naiem Issa

Sophia Bortnick

Email: sbortnick@thectnx.com

Metro Boston Clinical Partners

Recruiting

Brighton,Massachusetts,02135,United States

Mark Amster

William Calder

Phone: 617-783-7100
Email: wcalder@metrobostoncp.com

Apex Clinical Research Center LLC

Recruiting

Mayfield Heights,Ohio,44124,United States

Hannah Snyder

Email: hsnyder@apexskin.com

Jorge Garcia-Zuazaga

Cameron Dermatology

Recruiting

New York,New York,10023,United States

Jennie Mata

Email: jmata@equity-med.com

Michael Cameron

Care Access Alexandria

Recruiting

Arlington,Virginia,22206,United States

David Bray

Nicole Thornton

Email: Nicole.Thornton@careaccess.com

Skin Specialists PC

Recruiting

Omaha,Nebraska,68144,United States

Joel Schlessinger

Samantha Jo Johnson

Phone: 402-334-7546
Email: sam.johnson@lovelyskin.com

USC Keck School of Medicine

Recruiting

Los Angeles,California,90033,United States

Katrina Lee

Raveena Ghanshani

Email: raveena.ghanshani@med.usc.edu

Ctr for Dermatology Clinical Res

Recruiting

Fremont,California,95438,United States

Natalya Likhareva

Phone: 510-797-0140
Email: natalyal@ctr4derm.com

Sunil Dhawan

Clinical Research Inst of MI

Recruiting

Chesterfield,Michigan,48047,United States

Karie Simons

Email: ksimons@researchmi.com

Natalia Filipof

Clinical Research Ctr of Carolinas

Recruiting

Charleston,South Carolina,29407,United States

Amber Thompson

Phone: 843-556-8886
Email: amber.thompson@dermandlaser.com

Todd Schlesinger

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information

below.

Novartis Pharmaceuticals

Phone: +41613241111
Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: 1-888-669-6682
Email: novartis.email@novartis.com

Source URL: *https://prod1.novartis.com/clinicaltrials/study/nct06840392*

List of links present in page

1. https://clinicaltrials.gov/ct2/show/NCT06840392
2. #trial-eligibility
3. tel:614-293-4434
4. mailto:robert.furlong@osumc.edu
5. mailto:jbinder@northshore.org
6. mailto:janaya.patron@careaccess.com
7. tel:512-259-2545
8. mailto:jmcminn@atxresearch.com
9. tel:281-333-2288
10. mailto:dyetman@ccstexas.com
11. tel:615-859-0900
12. mailto:mary.smith@objective.health
13. mailto:yvilla@floridianresearch.com
14. tel:937-245-7500
15. tel:516-719-3376
16. mailto:kpasram1@northwell.edu
17. mailto:inoblitt@accurateclinicalmanagement.com
18. mailto:cnardi@soinct.com
19. mailto:stephenfuller@cctresearch.com
20. mailto:angela@totalskinandbeauty.com
21. mailto:sbortnick@thectnx.com
22. tel:617-783-7100
23. mailto:wcalder@metrobostoncp.com
24. mailto:hsnyder@apexskin.com
25. mailto:jmata@equity-med.com
26. mailto:Nicole.Thornton@careaccess.com
27. tel:402-334-7546
28. mailto:sam.johnson@lovelyskin.com
29. mailto:raveena.ghanshani@med.usc.edu
30. tel:510-797-0140
31. mailto:natalyal@ctr4derm.com
32. mailto:ksimons@researchmi.com
33. tel:843-556-8886
34. mailto:amber.thompson@dermandlaser.com
35. tel:+41613241111
36. mailto:novartis.email@novartis.com
37. tel:1-888-669-6682
38. mailto:novartis.email@novartis.com